Application of remazolam combined with propofol in bronchoscopy in elderly patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300071137

Enrollment

Unknown

Registered

2023-05-05

Start date

2023-05-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

disease of respiratory system

Interventions

propofol group:N/A

Remimazolam group:N/A

propofol and remimazolam group:N/A

Eligibility

Sex/Gender

All

Age

65 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients were selected for painless bronchoscopy or treatment, regardless of gender, age >65 years, ASA?-? grade

Exclusion criteria

Exclusion criteria: BMI>35, Myocardial infarction within 6 weeks, severe COPD, respiratory failure, SPO2<90% (inhaled air), lung function: FVC<15ml/kg, FEV1<1000ml or FEV1/FVC<35%, Mallampati score =4, allergy to study medication

Design outcomes

Primary

Measure	Time frame
SPO2;respiratory rate;	—

Countries

China

Contacts

Public ContactDongmei Ma

The Fourth Affiliated Hospital of Zhejiang University Medical College

8019111@zju.edu.cn+86 15267358077

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026